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Despite its importance as the leading cause of vascular dementia, the primary pathogenic mechanisms in
subcortical ischemic vascular dementia (SIVD) have remained elusive. Because of the lack of approved
therapeutic agents for SIVD, there is a pressing need to identify novel therapeutic targets. Comparative
lipidomic analyses of SIVD and mixed dementia (i.e., SIVD and Alzheimer’s disease, MixD) may also
confer new insights pertaining to the possible interaction between neurodegenerative and vascular
mechanisms in the pathogenesis of dementia. Liquid chromatography coupled to mass spectrometry was
used to comprehensively analyze the lipidomes of white and gray matter from the temporal cortex of
nondemented controls, SIVD, and MixD subjects. Detailed molecular proﬁles highlighted the pathologic
relevance of gray matter sphingolipid fatty acyl chain heterogeneity in dementia. In addition, the levels of
sulfatides and lysobisphosphatidic acids were progressively increased in the temporal cortex gray matter
from control to SIVD to MixD. White matter phospholipid proﬁles indicated possible adaptive mecha-
nisms (i.e., increased unsaturation) to chronic ischemia in SIVD and elevated membrane degradation in
MixD.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Subcortical ischemic vascular dementia (SIVD) is considered a
more clinically homogenous subtype of vascular dementia (VaD)
and represents a leading cause of vascular cognitive impairment
and dementia, arising primarily from small-artery disease and
hypoperfusion (Román et al., 2002). SIVD is predominantly the
result of both complete infarcts (lacunar infarcts and microinfarcts)
and rarefaction in the deep cerebral white matter, also termed
white matter lesions (Román et al., 2002). Although SIVD accountse CC BY license (http://
olecular and Developmental
iology, Chinese Academy of
ad, Chaoyang District, Beijing
ript.
Published by Elsevier Inc. All righsubstantially for cases of cognitive decline in the elderly individuals,
it often remains undiagnosed (Román et al., 2002). Given the
relatively long prodromal period for the development of dementia,
a therapeutic window may be available for medical intervention
before the onset of frank cognitive and behavioral symptoms if
accurate diagnosis could bemade at the preclinical or pre-dementia
stage (Exalto et al., 2012; Frisoni et al., 2010). The identiﬁcation of
reliable markers that could delineate the early pathogenic events in
dementia could therefore alleviate the escalating public health
burden associated with the disease (O’Brien et al., 2003).
In the last decade, considerable progress had been achieved in
understanding the Alzheimer’s disease (AD), both in terms of
elucidating disease pathogenesis and developing treatment strate-
gies, which is in stark contrast to the dearth of novel data pertaining
to VaD (O’Brien et al., 2003). Currently, there are no approved
medications available for treating VaD, and treatment is usually
conﬁned to controlling associated vascular risk factors such as hy-
pertension and dyslipidemia (Moretti et al., 2011). Furthermore,ts reserved.
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ment of AD displayed limited, if any, beneﬁt to VaD patients
(Simonsen et al., 2012). Thus, there is a pressing need to identify
novel therapeutic agents effective for VaD treatment. Studies that
address the role of brain lipid aberrations in VaD pathogenesis
have been particularly scarce, especially in the recent decade.
Perturbation of brain lipid homeostasis in VaD had been previously
investigated by Wallin et al. (1989) chieﬂy using thin-layer chro-
matography. The group reported substantial reductions in cerebro-
sides and sulfatides, and to a smaller extent, cholesterols and
phospholipids in the white matter of VaD and AD patients, respec-
tively (Wallin et al., 1989). Nonetheless, systematic proﬁling of the
comprehensive brain lipidome of VaD patients is still lacking and
therefore requires comprehensive instrumental analyses. Indeed,
molecular species within the same lipid class could be altered to
varying extent or even in a reciprocalmannerdependingon the level
of unsaturation and/or fatty acyl chain lengths, as had been previ-
ously demonstrated by Chan et al. (2012) in postmortem AD brain
tissues and AD mouse models. Thus, the elucidation of a precise
molecular lipid signature that deﬁnes SIVD is prerequisite for deci-
phering the mechanistic roles of lipids in dementia stemming from
vascular-related pathologies. The clinically homogenous nature of
SIVD, as well as its status as the leading cause of vascular-related
dementia in the elderly individuals (Román et al., 2002), renders it
a suitable candidate for investigating the role of lipids in VaD
pathogenesis.
Mounting evidence indicate the frequent coexistence of brain
vascular lesions and neurodegenerative changes in cognitively
impaired individuals (Petrovitch et al., 2005), and it was found that
these disorders were often juxtaposed in most population samples
(Snowdon et al., 1997). For instance, in the Honolulu-Asia Aging
Study, neuropathological examination of demented individuals
revealed an appreciable overlap, as well as autonomous contribu-
tions of AD pathology and vascular infarcts to the development of
dementia (Petrovitch et al., 2005). Indeed, these distinct categories
of brain pathologies could possibly produce synergistic effects
culminating in the clinical expression of cognitive impairment and
dementia, known as mixed dementia (MixD) (O’Brien et al., 2003),
deﬁned originally by Hachinski, (1990) as “Alzheimer’s disease and
cerebral infarcts contributing to the dementia”. Possibly, vascular
damages could reduce the threshold for the clinical manifestation
of AD (Esiri et al., 1999; Exalto et al., 2012). Accumulating data have
shown that the occurrence of pure VaD is rare compared with the
mixed phenotype (Enciu et al., 2011). Moreover, vascular risk fac-
tors including hypertension, hyperlipidemia, diabetes mellitus, and
the metabolic syndrome predispose individuals to both AD and
SIVD (de la Torre, 2010). Indeed, vasculopathy (and the resultant
ischemia) had long been proposed as an alternative etiology of AD
apart from the broadly accepted amyloid hypothesis (de la Torre,
2004; Pluta and Amek, 2008; Scheibel et al., 1989). In fact, in his
seminal work in 1907, Alzheimer also noted cerebrovascular aber-
rations of the endothelial walls, particularly for small vessels in the
brains of AD patients, which received considerably less attention
comparedwith amyloid-beta aggregates and neuroﬁbrillary tangles
that now constitute the hallmark features of AD (Pluta and Amek,
2008). The co-occurrence of disease phenotypes implies that
vascular defects and neurodegenerative changes may interact on
several levels. Elucidating the molecular details of such in-
teractions, as well as the respective contributions of vascular and
Alzheimer’s pathology to cognitive deﬁcits in MixDmight therefore
help identify the primary pathogenic mechanism in AD per se.
In this study, we report the comprehensive lipidomic proﬁling of
the white matter and gray matter from the temporal cortex of
patients with SIVD and MixD, respectively, and in comparison to
age-matched, nondemented controls using high-performanceliquid-chromatography coupled to mass spectrometry (HPLC/MS)
as the principal analytical platform. To our knowledge, this is the
ﬁrst lipidomic study to systematically characterize the distinct
brain lipid molecular signatures of SIVD and MixD patients. Asso-
ciation between brain lipid proﬁles and neuropathological param-
eters for dementia (i.e., neuritic plaques and neuroﬁbrillary tangles)
were also investigated by comparing variations in the lipidomic
patterns as a function of increasing senile plaque densities and tau
pathology. This study (1) identiﬁes novel molecular therapeutic
targets for SIVD; and (2) confers new insights pertaining to the
interactions between vascular and neurodegenerative lipid pa-
thology in contributing to dementia.
2. Methods
2.1. Subjects and tissue processing
Postmortem frozen brain tissues from SIVD, MixD, and age-
matched normal control subjects (Supplementary Table S1) were
obtained from the Newcastle Brain Tissue Resource, Institute for
Ageing and Health, Newcastle University. Informed consent was
obtained from the guardians of the patients before donation of
brain tissues and approval was granted by local research ethics
committees (National University Health System, Singapore and
Newcastle upon Tyne Hospitals Trust, UK). For this study, we
assessed samples of both gray and white matter from the temporal
lobe (Brodmann area 21). We focused on the temporal lobe because
medial temporal lobe atrophy is a common ﬁnding in dementia and
our recent study suggested a vascular basis for neurodegeneration
(Gemmell et al., 2012). The temporal lobe is also relatively free of
large infarcts (Kalaria et al., 2004).
Final classiﬁcation of subjects was assigned based on established
neuropathological diagnostic criteria. Brieﬂy, hematoxylineeosin
stainingwas used for assessment of structural integrity and infarcts,
Nissl and Luxol fast blue staining for cellular pattern and myelin
loss, Bielschowsky silver impregnation for “CERAD” rating of
neuritic plaques (Mirra et al., 1991) and tau immunohistochemistry
for “Braak” staging of neuroﬁbrillary tangles (Braak and Braak,
1991). A diagnosis of SIVD was made when there were multiple
or cystic infarcts, lacunae, microinfarcts, and small vessel disease,
and Braak stage < III (Kalaria et al., 2004). The diagnosis of MixD
was assigned when there was evidence of signiﬁcant AD pathology,
namely Braak stage V-VI, and moderate-severe vascular pathology.
Vascular pathology was graded according to the scoring system
described previously (Deramecourt et al., 2012). Control subjects
had no clinical evidence of dementia, neurologic, or psychiatric
disease. The age-matched controls had no history of cognitive or
psychiatric symptoms and died from nonneurologic causes such as
bronchopneumonia, pulmonary embolism, and cardiac failure. At
postmortem, control brains were Braak stage III or below and did
not meet diagnostic criteria for AD (Mirra et al., 1991) or SIVD
(Kalaria et al., 2004). Furthermore, tissue samples from controls
were determined not to have sufﬁcient pathology to reach the
threshold to ascertain a diagnosis for dementia.
2.2. Lipid extraction
Frozen tissues were inactivated with 900 mL of chlor-
oform:methanol (1:2) containing 10% deionized H2O. Tissue sam-
ples were cut into ﬁne pieces using micro-scissors on dry ice, and
methanol was used to thoroughly wash the micro-scissors between
samples. Samples were homogenized and incubated at 1200 rpm,
4 C, for 1 hour in a thermomixer. At the end of the incubation, 400
mL of deionized H2O and 300 mL of chloroform were added and
vortexed. Samples were then centrifuged at 12000 rpm, 4 C, for
S.M. Lam et al. / Neurobiology of Aging 35 (2014) 2369e2381 23715 minutes. Lower organic phase was extracted. Second extraction
was carried out by adding 50 mL of 1 M hydrochloric acid and 500 mL
of chloroform. Extracted organic fractions were pooled and dried
speed-valco (Thermo Savant, Milford, USA). Samples were stored
at 80 C until further analysis.
2.3. Mass spectrometric analysis
Polar lipids were analyzed on an Agilent 1200 HPLC system
coupled with an Applied Biosystem Triple Quadrupole/Ion Trap
mass spectrometers 3200 Qtrap as described previously (Shui et al.,
2011a,b). PC-14:0/14:0, PE-14:0/14:0, PS-14:0/14:0, PA-17:0/17:0,
PG-14:0/14:0, PI-34:1/d31, LPC-C20:0, LPE-C17:0, C8-GluCer, C17-
Cer, C14-LBPA, C12-SM, C12-SL were obtained from Avanti Polar
Lipids (Alabaster, AL, USA). Dioctanoyl phosphatidylinositol (PI,
16:0-PI) was used for lysophosphatidylinositol quantitation and
obtained from Echelon Biosciences, Inc (Salt Lake City, UT, USA).
Glycerol lipids triacylglycerides (TAG) and diacyglycerides (DAG)
were analyzed using a modiﬁed protocol of reverse-phase HPLC/
ESI/MS described previously (Shui et al., 2010). Separation of lipids
aforementioned was carried out on a Phenomenex Kinetex 2.6m-
C18 column (i.d. 4.6  100 mm) using an isocratic mobile phase
chloroform:methanol:0.1 M ammonium acetate (100:100:4) at a
ﬂow rate of 150 mL/min for 17 minutes. Levels of TAG were calcu-
lated relative to the spiked d5-TAG 48:0 internal standard (CDN
isotopes), while DAG species were quantiﬁed using 4 ME 16:0
Diether DG as an internal standard (Avanti Polar Lipids, Alabaster,
AL, USA). Free cholesterol and cholesterol esters were analyzed as
described previously with corresponding d6-cholesterol and d6-
C18 cholesterol ester (CDN isotopes) as internal standards (Shui
et al., 2011a,b).
3. Statistical analysis
Molar fractions of individual lipid classes and species were used
for statistical analyses. One-way analysis of variance with post hoc
Tukey test was performed to compare the changes in lipid proﬁles
between control, SIVD, and MixD. To evaluate the associations be-
tween neuropathological parameters (i.e., CERAD plaque score,
Braak staging) and lipid changes, subjects were classiﬁed into
separate groups based on CERAD plaque score (Group 1: none/
sparse; Group 2: moderate/frequent) and Braak staging (Group 1:
0eIV; Group 2: VeVI), respectively. Student t test was used to
compare the changes in lipid proﬁles between the 2 groups within
each clinical classiﬁcation. For all bar graphs, error bars represent
standard errors of themean. For all cases, #p< 0.10; *p< 0.05; **p<
0.01; ***p < 0.001.
4. Results
A total of 334 distinct lipid species from 17 lipid subclasses
including neutral lipids such as cholesteryl esters, free cholesterols,
DAG, TAG; sphingolipids including ceramides (Cer), galactosylcer-
amides (GalCer), glucosylceramides (GluCer), sphingomyelins (SM),
ganglioside mannoside 3 (GM3), and sulfatides (SL); as well as
phospholipid subclasses of phosphatidylcholines (PC), phosphati-
dylethanolamines (PE), phosphatidylglycerols (PG), phosphatidyli-
nositols (PI), phosphatidylserines (PS), phosphatidic acids (PA), and
lysobisphosphatidic acids (LBPA) were analyzed. The purity of the
white and gray matter obtained in this study was veriﬁed based on
their respective molecular compositions of plasmalogen phospha-
tidylethanolamine species (pPE) (Han et al., 2001) (Supplementary
Fig. S1). Interestingly, global alterations in lipid proﬁles for SIVD
patients were concentrated in the white matter (Supplementary
Fig. S2), whereas that for MixD (i.e., AD þ VaD) were mainlylocalized to the gray matter (Supplementary Fig. S3). These obser-
vations were aligned with the neuropathophysiology of the
respective diseases, because SIVD is largely characterized by
vascular lesions of the cerebral white matter (Román et al., 2002;
Tomimoto, 2011), while AD essentially entails a dysfunction of
chemical synapses coupled with degeneration of the hippocampal
neurons (Dubois et al., 2010; Selkoe, 2002), both of which are
mainly found in the gray matter of the brain tissues.
4.1. Overall reductions in sphingolipids in SIVD white matter
Signiﬁcant reductions in the classes of GalCer and SL (p < 0.05)
were observed in SIVD white matter, in corroboration with Wallin
et al. (1989), who observed decreases in cerebrosides and SL in
VaD. In addition, Cer and GluCer were also decreased albeit not
reaching statistical signiﬁcance, while total SM was increased. Also
in agreement with previous study based on thin-layer chromatog-
raphy (Wallin et al., 1989), total GM3 levels were not signiﬁcantly
altered (Fig. 1A). Molecular proﬁles of the sphingolipidome showed
that Cer species comprising short-chain fatty acyls (16e18C) were
elevated, while the levels of very long chain (VLC)-Cer (24C) were
speciﬁcally reduced (p < 0.05) (Fig. 2A). Parallel increases in short-
chain SMwith the corresponding fatty acyl chain lengths (p < 0.05)
(Fig. 2B) were observed, accompanied by diminished levels of C18-
GluCer (Fig. 2C). Notably, GM3 18:1/16:1 exhibited w25% increase
in SIVD compared with control (p < 0.05) (Fig. 2D). On the other
hand, individual species of GalCer and SL were all consistently
reduced in SIVD white matter (Fig. 2E and F). The speciﬁc increases
in short-chain Cer and SM in SIVD white matter suggested that
excess short-chain Cer were probably channeled into SM, resulting
in diminished levels of other downstream glycosphingolipids
including GluCer, GalCer, and SL with the corresponding fatty acyl
moieties. On the other hand, the overall reductions in glyco-
sphingolipids containing VLC-fatty acyls might have resulted from
the attenuated biosynthesis of VLC-Cer upstream.
4.2. Changes in phospholipids in SIVD white matter
Contrary to the overall reductions in the white matter sphin-
golipidome, appreciable increases were observed in numerous
phospholipid classes including PC, PS, and PG (p < 0.05) (Fig. 1B).
Notably, individual species of PC, PS, and PG were also predomi-
nantly elevated in SIVD with statistical signiﬁcance (p < 0.05)
(Fig. 3AeC). The trend was remarkably striking for PG with w1.5-
fold increase, for which all individual species were also consis-
tently increased (Fig. 3B). Also notable is that the levels of several
polyunsaturated PS, such as PS 36:3, PS 36:4, PS 38:4, PS 40:7, PS
40:5, and PS 40:4, were speciﬁcally augmented in SIVD (p < 0.05)
(Fig. 3C). While total PE did not change appreciably (Fig. 1A), mo-
lecular compositions of pPE were altered according to their levels of
unsaturation. Notably, PE 36:2p, 36:3e, the most abundant species
in nondemented controls, were reduced substantially in SIVD while
PE 40:6p, 40:7e was increased with marginal signiﬁcance (p< 0.10)
(Fig. 3D). On another note, most diacyl-PE species were increased in
SIVD (Fig. 3D).
4.3. Enhanced sphingolipids levels in MixD gray matter
The levels of various sphingolipid classes were predominantly
increased in MixD gray matter (Fig. 4). With the exception of SM
and GM3, which exhibited changes dependent on fatty acyl het-
erogeneity (see the following), total Cer (p < 0.05), GluCer (p <
0.05), GalCer (p < 0.10), and SL (p < 0.05) were all appreciably
increased in MixD gray matter (Fig. 1B). Detailed molecular proﬁles
indicated that VLC-Cer (22e24C) were signiﬁcantly enriched
Fig. 1. Changes in the levels of individual lipid subclasses amongst control (n ¼ 14), SIVD (n ¼ 11), and MixD (n ¼ 10) for (A) white matter and (B) gray matter. Lipid classes were
expressed as mean molar fractions with error bars indicating mean  standard errors. Abbreviations: MixD, mixed dementia; SIVD, subcortical ischemic vascular dementia.
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sponding fatty acyls (Fig. 4B). In contrast, SM species comprising
shorter fatty acid residues (18e20C) were signiﬁcantly reduced in
MixD gray matter (Fig. 4B). The reciprocal changes in SM based on
fatty acyl chain lengths were in agreement with previous obser-
vations in postmortem prefrontal cortex but surprisingly opposite
to that in the entorhinal cortex of AD human brains (Chan et al.,2012). While individual species of GluCer were all consistently
increased (Fig. 4C), short-chain GM3 (16e20C) were reduced
compared with control, albeit not reaching statistical signiﬁcance
(Fig. 4D). On the other hand, VLC-GM3 displayed remarkable in-
creases in MixD, withw2-fold increase observed for GM318:1/24:1
and GM3 18:1/24:0 (p < 0.05) (Fig. 4D), which coincides with the
reported selective enrichment of VLC-GM3 in human AD entorhinal
Fig. 2. Comparative lipid proﬁles of sphingolipids including (A) Cer, (B) SM, (C) GluCer, (D) GM3, (E) GalCer, and (F) SL in the white matter of control (n ¼ 14), SIVD (n ¼ 11),
and MixD (n ¼ 10). Lipid species were expressed as mean molar fractions with error bars indicating mean  standard errors. Abbreviations: Cer, ceramides; GalCer,
galactosylceramides; GM3, ganglioside mannoside 3; GluCer, glucosylceramides; MixD, mixed dementia; SIVD, subcortical ischemic vascular; SL, sulfatides; SM,
sphingomyelins.
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Fig. 3. Heatmaps illustrate the fold change in individual phospholipid species in the white matter of SIVD and MixD compared against control from the subclasses of (A) PC, (B) PG,
(C) PS, and (D) PE. Abbreviations: PC, phosphatidylcholines; PE, phosphatidylethanolamines; PG, phosphatidylglycerols; PS, phosphatidylserines.
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GalCer and SL were consistently increased in MixD gray matter
compared with controls (Fig. 4E and F). In accordance with our
observed increase in SL with neuropathology, Lim et al. (2013) had
previously reported enhanced SL levels in aged apolipoprotein E
(APOE)-ε4 knock-in mice compared with their ε3 counterparts
under high-fat-high-cholesterol diet, and that individual SL species
were predominantly increased with aging regardless of both diet
and APOE genotype (Lim et al., 2013).Therefore, a discernible metabolic shift toward elevated levels of
glycosphingolipids, instead of SM, was noted in MixD. In addition,
as the levels of relatively short-chain Cer (16e20C) were only
modestly increased in MixD, degradation of SM with the corre-
sponding fatty acyls might have occurred to generate additional Cer
that would serve as precursors for the biosynthesis of short-chain
glycosphingolipids further downstream. Notably, long-chain SL
(22e24C) exhibited progressive increases from control to SIVD to
MixD (Fig. 4F), suggesting that interaction between vascular and
Fig. 4. Comparative lipid proﬁles of sphingolipids including (A) Cer, (B) SM, (C) GluCer, (D) GM3, (E) GalCer, and (F) SL in the gray matter of control (n ¼ 14), SIVD (n ¼ 11), and MixD
(n ¼ 10). Lipid species were expressed as mean molar fractions with error bars indicating mean  standard errors. Abbreviations: Cer, ceramides; GalCer, galactosylceramides; GM3,
ganglioside mannoside 3; GluCer, glucosylceramides; MixD, mixed dementia; SIVD, subcortical ischemic vascular; SL, sulfatides; SM, sphingomyelins.
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on this speciﬁc class of lipids in the gray matter.
4.4. Alterations in phospholipids in MixD gray matter
Major phospholipid classes of PC (p < 0.05) and PE (p < 0.10), as
well as total PG (p < 0.05) were signiﬁcantly reduced in MixD
compared with controls (Fig. 1B). In addition, total lyso-PC
(including lyso-ether PC) was decreased (p < 0.05) (Fig. 1B). Mo-
lecular proﬁling indicated that while diacyl-PC were predomi-
nantly reduced, several plasmalogen-PC (pPC) species including
PC34:1p, PC34:0p, PC36:3p, PC 36:2p, PC 36:1p, and PC 38:4p were
signiﬁcantly enriched (p < 0.05) in MixD (Fig. 5A). In addition, in
agreement with Chan et al. (2012), all individual PG (Fig. 5B) and
lyso-PC (including lyso-ether PC) species (Fig. 5C) were consis-
tently decreased. On another note, numerous PA species such as PA
32:1, PA 36:2, and PA 36:1 were signiﬁcantly elevated (p < 0.05)
(Fig. 5D). Notably, total LBPA were enriched by w1.8-fold in MixDFig. 5. Heatmaps illustrate the fold change in individual phospholipid species in the gray mat
Lyso-PC, (D) PA, (E) LBPA, and (F) PE. Abbreviations: LBPA, lysobisphosphatidic acids; Mix
dylethanolamines; PG, phosphatidylglycerols; PS, phosphatidylserines.compared with control (Fig. 1B), which is in close agreement with
the reportedw1.8-fold increase in LBPA in the entorhinal cortex of
AD human brains (Chan et al., 2012). Moreover, total LBPA (Fig. 1B)
and individual LBPA species (Fig. 5E) exhibited progressive in-
creases from control to SIVD to MixD (Fig. 1B). Contrary to a pre-
vious report (Han et al., 2001) but in accordance with Chan et al.
(2012), no signiﬁcant changes in total pPE were observed in
MixD (Supplementary Fig. S4A and B). Nonetheless, poly-
unsaturated pPE such as PE 40:6p, 40:7e was signiﬁcantly reduced
(p < 0.05), while less unsaturated pPE including PE 34:1p, 34:2e
and PE 36:2p, 36:3e were increased (p < 0.05) (Fig. 5F). Indeed, an
overall reduction in polyunsaturated pPE (n  4) was observed in
MixD gray matter, accompanied by concomitant increases in pPE
containing only 1 (p < 0.05), 2 (p < 0.01), or 3 (p < 0.05) double
bonds in their structures (Supplementary Fig. S4D). On the other
hand, total diacyl-PE (p < 0.01) (Supplementary Fig. S4B), as well as
several individual diacyl-PE species, were signiﬁcantly reduced in
MixD (Fig. 5F).ter of SIVD and MixD compared against control from the subclasses of (A) PC, (B) PG, (C)
D, mixed dementia; PA, phosphatidic acids; PC, phosphatidylcholines; PE, phosphati-
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Signiﬁcant increases in total DAG (p< 0.01), aswell as decreases in
total SM (p< 0.05), PE (p< 0.05), and PS (p< 0.01) were observed in
the gray matter of subjects with higher CERAD plaque score (i.e.,
moderate and/or frequent) (Section 2.4) (Fig. 6A). Interestingly,
numerous DAG species comprising palmitic (C16:0), palmitoleic
(C16:1), stearic (C18:0), andoleic acids (C18:1) in their structureswere
markedly enriched in subjects with higher CERAD (Fig. 6B). Accord-
ingly, totalDAG (p< 0.05) (Fig.1B) and similarDAG species containing
saturated and/ormonounsaturated fatty acids were also signiﬁcantly
elevated (p < 0.05) in MixD gray matter (Supplementary Fig. S3),
which is in corroborationwith previous observation in the prefrontal
cortex of AD human brains (Chan et al., 2012). On the other hand,
consistentwith changes in SM inMixD graymatter, the reductions in
relatively short-chain SM (18e20C) were also noted in subjects with
higher CERAD (Fig. 6C). Remarkably, numerous polyunsaturated PS
such as PS 36:4, PS 40:6, PS 40:5, and PS 40:4 were considerably
reduced (p< 0.05)with higher CERAD (Fig. 6D). Furthermore, PS 40:6
(p < 0.05), PS 40:5 (p < 0.01), and PS 40:4 (p < 0.001) were also
signiﬁcantly decreased inMixD gray matter (Supplementary Fig. S3).
In addition, changes in pPE according to the levels of unsaturation,
similar to that observed in MixD gray matter, were also noted in
subjects with higher CERAD. Diacyl-PE, on the other hand, was
consistently reduced with higher CERAD (Fig. 6E). No associations
between lipid changes in the temporal cortex and the Braak staging,
however, were found in both the white and gray matter.
5. Discussion
While SIVD mainly affects the subcortical structures, the choice
of the cortex for lipidomic analysis could potentially yield lipid
changes that are etiologically linked to the subcortex on a circuit-
wide basis, such as those affecting neurotransmission. Therefore,
the observed lipid derangements in the cortex, instead of the
damaged tissues in the subcortical regions, possibly reﬂect primary
pathogenic events associated with the early stage of the disease. In
addition, cortical regions appear less susceptible to postmortem
damage and could therefore better indicate changes of patho-
physiological relevance (Bowen et al., 1977).
5.1. Sphingolipid aberrations in SIVD indicated disruptions to
myelin structural integrity
Because cerebrosides are largely conﬁned to myelin, the
considerable reductions in GluCer, GalCer, and SL in SIVD white
matter suggested that the myelin sheath represents a primary site
of these changes, consistent with previous observations of exten-
sive myelin destruction with relatively minor neuronal damages in
VaD (Wallin et al., 1989). It had been shown that oligodendrocytes
swelling and myelin sheath aberrations occurred before (and
independently of) neuronal damage in the event of ischemia
(Pantoni et al., 1996). It is thus probable that under hypoperfusion
in SIVD, available oxygen is preferentially channeled to preserve the
functionally important neurons, leading to selective death of oli-
godendrocytes that also have considerably highmetabolic demands
(Wallin et al., 1989). Indeed, GalCer and SL are almost exclusively
synthesized by oligodendrocytes (Bosio et al., 1996; Coetzee et al.,
1998). This also explains the predominant localization of vascular
lesions to the white matter, rather than the gray matter, of the
temporal cortex observed in the present study.
Surprisingly, the sphingolipid and neutral lipid derangements
observed in SIVD white matter closely resembled the brain lipid
proﬁles of ceramides synthase 2 (CerS2)-null mice previously re-
ported in an independent study (Ben-David et al., 2011). CerS2preferentially uses VLC acyl-CoAs (22e24C) for biosynthesis of VLC-
Cer (Laviad et al., 2008). In CerS2-null mice, reductions in C22-C24-
Cer and C22-C24-SM were observed, accompanied by concomitant
increases in C18-Cer and C18-SM and an overall reduction in GalCer.
In addition, a marginal increase in cholesteryl esters was reported
(Laviad et al., 2008). Notably, CerS2-null mice exhibited myelin
degeneration and detachment from axons without appreciable
neuronal loss, coupled with motor dysfunction characterized by
fast myoclonic jerks and loss of posture, which were indicated to be
of a subcortical origin from electroencephalogram recordings
(Laviad et al., 2008). Indeed, white matter lesions and psychomotor
disturbances also represent the major neuropathological and clin-
ical manifestations of SIVD (Tomimoto, 2011).
5.2. Enhanced phospholipid unsaturation in SIVD as an adaptive
response to chronic ischemia
The increase in phospholipid content in SIVD white matter con-
trasted with earlier studies reporting phospholipid catabolism in
transient cerebral ischemia, which could be attributed to (1) lipid
peroxidation; and/or (2) activation of hydrolytic enzymes (Yoshida
et al., 1980). Nonetheless, a separate study argued against phospho-
lipid membrane disintegration but pointed instead to an augmented
levelofpolyunsaturated fattyacids, during ischemia (Rehncronaetal.,
1982). The paradoxical increase in polyunsaturated pPE and PS under
chronic hypoperfusion in SIVDmight be associated with the location
of white matter tissues chosen for analysis. Previous analysis had
reported the predominant localization of parenchymal lesions in the
frontal and parietal lobes, instead of the temporal lobe, in SIVD
(Akiguchi et al., 2004). Thus, the small vessels in the temporal lobe
might be less severely affected in SIVD, or only afﬂicted at advanced
stages. Therefore, the observed enhancement in phospholipid unsa-
turation in the temporal cortex might be associated with “remote
ischemic preconditioning” (Steiger and Hänggi, 2007), in which pro-
longed ischemia experienced in the frontal and parietal lobes might
possibly trigger adaptive mechanisms (e.g., increase unsaturation) in
the temporal cortex for protection against impending oxidative in-
sults. Notably, ischemic preconditioning had been reported to
enhance antioxidants in the brain and peripheral organs following
cerebral ischemia (Glantz et al., 2005).
5.3. Polar lipid changes in MixD consistent with endolysosomal
dysfunction and increased oxidative stress characteristic of AD
molecular pathology
The global increase of sphingolipids (and LBPA) is in accord with
the endolysosomal dysfunction theory for AD pathogenesis (Small
and Gandy, 2006). A notable ﬁnding in our study is the reciprocal
changes in SM and GM3 depending on fatty acyl heterogeneity in
theMixD graymatter, whichmight be attributed to the critical roles
of fatty acid chain lengths in mediating endocytic trafﬁcking and
lipid raft functions. Speciﬁcally, cholesterol loading was shown to
elevate intracellular accumulation of long-chain SM via enhanced
targeting of these species for recycling back to the plasma mem-
brane, instead of degradation in lysosomes (Koivusalo et al., 2007),
consistent with the observed increases in free cholesterols and VLC-
SM in this study (Supplementary Fig. S4B). SM and gangliosides
constitute important components of lipid rafts in neuronal mem-
branes (Haughey et al., 2010). The acyl chain components of raft
lipids could exert varying yet determining effects on the stability of
individual membrane rafts, which may have far-reaching effects on
cellular signaling and biochemistry. Indeed, similar opposing trends
in GM3 based on fatty acid chain lengths had been observed in the
plasma of type 2 diabetes patients and GM3 fatty acyl heterogeneity
was proposed to inﬂuence lipid raft formation critical for mediating
Fig. 6. Changes in the selected classes of lipids in the gray matter as a function of increasing CERAD plaque score. The levels of (A) speciﬁc lipid subclasses and
individual species from subclasses of (B) DAG, (C) PS, (D) SM, and (E) PE were signiﬁcantly perturbed with increasing CERAD. Lipid species were expressed as mean molar
fractions with error bars indicating mean  standard errors. Abbreviations: DAG, diacyglycerides; PE, phosphatidylethanolamines; PS, phosphatidylserines; SM,
sphingomyelins.
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with short-chain GM3, the augmented levels of VLC-GM3 in gray
matter might be even more detrimental to AD pathogenesis, as the
longer fatty acyl chains are expected to confer stronger hydropho-
bic forces in overcoming the electrostatic repulsion between sialic
acid residues to form ganglioside-enriched membrane clusters,
previously shown to be involved in seeding amyloid-beta poly-
merization (Matsuzaki et al., 2010).
The overall reduction in major membrane phospholipids
including PC and PE in MixD coincided with previous observations
in AD, which attributed the decrease to membrane defects associ-
ated with neurodegenerative events (Nitsch et al., 1992; Pettegrew
et al., 2001). In addition, the overall reduction in diacyl-PC, as well
as increases in corresponding diacyl-PA and DAG species largely
comprising saturated and/ormonounsaturated fatty acids indicated
enhanced phospholipase D activity in MixD. Indeed, phospholipase
D-2 ablation had been previously shown to rescue AD-linked syn-
aptic dysfunction and cognitive deﬁcits in AD mouse model
(Oliveira et al., 2010).
5.4. Contribution of vasculopathology and neuropathology to mixed
dementia
While lipid changes in MixD gray matter were predominantly in
accordance with AD pathology, the progressive increase in SL fromFig. 7. Summary of the differences in perturbed sphingolipid metabolisms between SIVD w
synthesis was observed in SIVD white matter, an increased channeling of Cer for biosynth
arrows indicate increased channeling while dotted arrows indicate reduced channeling. The a
red indicating increase and green indicating reduction. Abbreviations: Cer, ceramides; MixDcontrol to SIVD to MixD contrasted with the previously reported SL
reduction in early AD (Han et al., 2002), and in the prefrontal and
entorhinal cortices of postmortem AD human brains (Chan et al.,
2012). The increase in gray matter SL in MixD might thus be
attributed to the additive effects of concurrent vascular lesions in
addition to neurodegenerative changes. Under normal physiolog-
ical condition, SL-containing APOE-associated lipoproteins are
either taken up by neurons and metabolized via the endolysosomal
pathway, or transported to the peripheral circulation and removed
from the brain tissues via the cerebrospinal ﬂuid (Han, 2007). A
general state of hypoperfusion in brain parenchyma in SIVD and
MixD could possibly impede the clearance of SL-containing lipo-
proteins via the cerebrospinal ﬂuid, which might be further exac-
erbated in MixD because of the compromised endolysosomal
pathway in neurons, leading to SL accumulationwithin graymatter.
Indeed, endolysosomal dysfunction might have commenced in
early SIVD, as evident in the progressive accumulation of LBPA in
gray matter from SIVD to MixD but the effect might have been
masked in SIVD because of attenuated glycosphingolipid synthesis
as discussed previously.
While current lipidomic data seemed to suggest that MixD
phenotype could be, to a greater extent, attributed to neuropath-
ological aberrations instead of vasculopathology, it is nonetheless
crucial to reckon that SIVD and AD might alter the brain paren-
chyma in a region-speciﬁc manner. As parenchymal lesions in SIVDhite matter and MixD gray matter. While an enhanced shunt of Cer precursors to SM
esis of complex glycosphingolipids downstream was noted in MixD gray matter. Bold
lterations in sphingolipid levels were subdivided based on fatty acyl chain lengths, with
, mixed dementia; SIVD, subcortical ischemic vascular; SM, sphingomyelins.
S.M. Lam et al. / Neurobiology of Aging 35 (2014) 2369e23812380appear predominantly in the frontal and parietal lobes (Akiguchi
et al., 2004), the choice of the temporal cortex for analysis could
possibly have biased the MixD lipidome toward a greater mani-
festation of neurodegenerative phenotype resembling AD.
5.5. Conclusions and future work
Lipidomics represents a useful tool that can be harnessed to
determine lipid pathways that are speciﬁcally perturbed in distinct
biological systems (Chan et al., 2012). Our study has therefore
established a reference frame of lipids that could be targeted for
advancing current diagnostic and therapeutic endeavors in the
context of SIVD and MixD. In particular, based on the close
resemblance in brain sphingolipid proﬁles of CerS2-null mice (Ben-
David et al., 2011) with the anomalies in SIVD sphingolipidome
reported herein, we surmise that CerS2 could be a candidate
enzyme implicated in SIVD pathogenesis that warrants further
investigation. Indeed, the mechanisms that connect small vessel
disease with brain parenchymal lesions have remained discordant
and elusive, primarily because of a lack of appropriate animal
models that can convincingly reﬂect the pathologic aberrations
observed in humans (Pantoni, 2010). Our lipidomic results suggest
that CerS2-null mice could be a potentially relevant model for hu-
man SIVD that warrants future investigation.
In addition, this study underscored the critical importance of
sphingolipid fatty acyl chain heterogeneity in neurodegeneration,
and demonstrated the essential differences in the perturbed
sphingolipid metabolisms between SIVD and MixD compared with
controls. In summary, enhanced channeling of Cer precursors to SM
biosynthesis was observed in SIVD white matter while biosynthesis
of complex glycosphingolipids downstream of Cer was curtailed.
The opposite was noted for MixD gray matter, in which a global
accumulation of glycosphingolipids was observed (Fig. 7).
Our study also identiﬁed SL accumulation in the temporal cortex
gray matter, which could likely be attributed to the synergistic in-
teractions between vascular and neurodegenerative lesions co-
occurring speciﬁcally in MixD, as a possible marker that could
distinguish pure AD from MixD. The feasibility of sulfatides as a
lipid marker to differentiate between SIVD and MixD from controls,
however, needs to be further evaluated in the cerebrospinal ﬂuid of
a human cohort, although region-speciﬁc aberrations in brain lipid
levels might be masked as a consequence. Furthermore, the path-
ogenic signiﬁcance of the lipid alterations reported herein also re-
quires veriﬁcation using appropriate animal models for SIVD and
MixD. Nevertheless, the present study has contributed substantially
to our existing knowledge of the possible associations between
brain lipid changes and the pathogenesis of dementia in a human
cohort, thus providing a framework uponwhich future mechanistic
validation can be conducted.
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